Drug Trial Radar · NCT03671018
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
422
Planned (sponsor's estimate)
Start
Sep 25, 2018
Primary completion
Jan 30, 2024
Study completion Jul 20, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of intravenous (IV) or subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). It will consist of a dose finding portion followed by an expansion phase for second line or later (2L+) participants with relapsed or refractory (R/R) DLBCL and 2L+ R/R FL. In addition, subcutaneous mosunetuzumab in combination with polatuzumab vedotin will be evaluated in participants with at least 2 prior lines of systemic therapy (3L+) for the treatment of R/R mantle cell lymphoma (MCL) and in participants with 2L+ R/R DLBCL.
Conditions
- B-cell Non-Hodgkin Lymphoma
Interventions
Mosunetuzumab (IV)Drug
Participants will receive intravenous (IV) mosunetuzumab.
Mosunetuzumab (SC)Drug
Participants will receive subcutaneous (SC) mosunetuzumab.
Polatuzumab vedotinDrug
Participants will receive IV polatuzumab vedotin.
TocilizumabDrug
Participants will receive IV tocilizumab as needed.
RituximabDrug
Participants will receive IV rituximab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab VedotinTime frame: Cycle 1 to Cycle 2 (cycle length = 21 days)
- Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab VedotinTime frame: Cycle 1 to Cycle 2 (cycle length = 21 days)
- Percentage of Participants with Adverse Events (AE)Time frame: Baseline through approximately 90 days after last study treatment
- Best Objective Response Rate (ORR), Defined as CR or Partial Response (PR) at any Time, Based on PET-CT and/or CT Scan, as Determined by the Independent Review Committee (IRC) using Standard Criteria for NHLTime frame: Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)
Locations
29 sites in 5 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham School of Medicine
Birmingham, Alabama
City of Hope
Duarte, California
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado
University of Miami Miller School of Medicine
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
University of Michigan Hospital
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
New York University Langone Medical Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh - Hillman Cancer Center
Pittsburgh, Pennsylvania
Lifespan Cancer Institute
Providence, Rhode Island
University of Texas M.D. Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Medical College of Wisconsin, Froedtert Hospital;Nephrology Section
Milwaukee, Wisconsin
UZ Brussel
Brussels, Belgium
CH Jolimont - Lobbes (Jolimont)
Haine-Saint-Paul, Belgium
Clinique St Pierre asbl
Ottignies, Belgium
Hamilton Health Sciences - Juravinski Cancer Centre
Hamilton, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Saskatchewan Cancer Agency (SCA) - Saskatoon Cancer Centre (SCC)
Saskatoon, Saskatchewan, Canada
Institut Catala d Oncologia Hospital Duran i Reynals
Barcelona, Spain
Hospital de San Pedro de Alcantara
Cáceres, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Hospital Infanta Leonor; Servicio de Hematologia
Madrid, Spain
Hospital Universitario Virgen Macarena; Servicio de Oncologia
Seville, Spain
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Plymouth Hospitals NHS Trust; Pharmacy Dept
Plymouth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.